Ultragenyx Exec Mansbach Joins 89bio as Chief Medical Officer

Hank Mansbach has been appointed chief medical officer of 89bio. Mansbach comes to the biotech startup from Ultragenyx (NASDAQ: RARE), where he was head of metabolic and neurology global clinical development. 89bio, which splits its operations between San Francisco and Herzliya, Israel, raised $60 million in financing last October to support its development of a drug for nonalcoholic steatohepatitis that it acquired from Teva Pharmaceutical (NYSE: TEVA).

Share the Article